In This Article:
HENDERSON, NV / ACCESSWIRE / September 7, 2018 / A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last ten trading session going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain of 3976% as we speak.
PPCB has a 52 week high of $0.77 which is an enormous increase from the current trading price. PPCB is currently preparing for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with an intriguing patent portfolio.
PPCB recently announced that it was selected to present at the 25th Annual NewsMakers in the biotech industry conference in New York City on September 7th, 2018. This is a major conference for such a small biotech company like PPCB, and PPCB could receive significantly increased attention from the street in the coming days. PPCB's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
Everyone that found PPCB before the upcoming conference have seen an incredible uptrend, and those that continue to find the company before its clinical trial could be in store for a great ride.
Here are two cancer stocks that have seen explosive gains:
Propanc Biopharma, Inc. (PPCB), and Verastem, Inc. (VSTM),
Propanc Biopharma, Inc. (PPCB)
Market Cap: $12.94M Share Price: $0.01551
Propanc Biopharma Inc., a clinical stage biopharmaceutical company focusing on the development of new treatments for cancer patients who have solid tumors such as pancreatic, ovarian and colorectal cancers. Interestingly enough, this company will begin to experience trials with human subjects. PRP is an FDA designated Orphan Drug, and by definition, it is an intravenous substance which is administered once a day. It is a combination of two pancreatic proenzymes: trypsinogen and chymotrypsinogen.
Propanc is currently readying for it's first in-human study, and PRP aims to prevent tumor recurrence and metastasis from solid tumors. As it is commonly known, most all cancers are solid tumors, and metastasis is the main cause of patient death from cancer. Unfortunately, millions of people died from cancer in 2012. A report by IMS Health states new therapies are causing the global oncology market to meet demand. This is expected to reach $150 billion by 2020. The Company's focus patient populations are pancreatic, ovarian and colorectal cancers. This represents an estimated combined market segment of $14 billion in 2020, according to GBI Research.